Treatment with STING ligands resulted in a significant secretion of IFNβ, and a trend towards increased TNFα secretion, but this did not reach statistical significance (Fig 2D) suggesting that as with other innate stimuli used to treat papilloma, production of type I IFN may be a major mechanism of action. The gene discussed is IFNB1; the disease is papilloma.